AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Drax Group PLC

Declaration of Voting Results & Voting Rights Announcements Jan 2, 2019

4844_rns_2019-01-02_7c759668-7cb5-4e9f-b7cb-c08b4f151358.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9854L

Drax Group PLC

02 January 2019

02 January 2019  

Drax Group plc

(Symbol: DRX)

TOTAL VOTING RIGHTS AND SHARE CAPITAL

In conformity with the Disclosure and Transparency Rules provision 5.6.1R, Drax Group plc (the "Company") advises of the following:

That, as at 31 December 2018, the Company's issued share capital consisted of 407,193,168 ordinary shares of 11 16/29 pence each, with each ordinary share having one vote, of which 13,023,639 ordinary shares are held in treasury.  Treasury shares do not carry voting rights.

The increase in the issued share capital is due to the allotment of 7,881 new shares to satisfy the exercise of share options in accordance with the rules of the Company's Sharesave Plan. 

Accordingly, the total number of voting rights in respect of these ordinary shares is 394,169,529.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their voting rights interest, or a change to that interest, in the Company under the FCA's Disclosure and Transparency Rules.

David McCallum

Company Secretary

Drax Group plc

- - ENDS - -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVRSSUFDEFUSEEF

Talk to a Data Expert

Have a question? We'll get back to you promptly.